Supportive Care in Low-Risk Myelodysplastic Syndromes: Role of Erythropoiesis Stimulating Agents (ESAs)

被引：0
|
作者：
Cerchione, Claudio [1 ]
Alfinito, Fiorella [2 ]
Giannini, Benedetta Maria [1 ]
Pane, Fabrizio [2 ]
Musuraca, Gerardo [1 ]
Martinelli, Giovanni [1 ]
机构：
[1] IRCCS, Hematol Unit, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, FC, Italy
[2] AOU Federico II, Naples, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
MDS; myelodysplastic syndromes; ESAS; supportive; care; erythropoietin;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-502
引用
收藏
页码：S318 / S318
页数：1
相关论文
共 50 条
  • [31] Low-risk myelodysplastic syndromes and iron overload
    Fenaux, Pierre
    HEMATOLOGIE, 2006, 12 : 9 - 9
  • [32] Erythropoietic-Stimulating Agents (ESAs) Are Not Associated with a Transient Risk of Deep Vein Thrombosis (DVT) in Myelodysplastic Syndromes (MDS)
    Sato, Masayo
    Smith, Sheila R. Weiss
    Davidoff, Amy
    Baer, Maria R.
    Ke, Xuehua
    Gore, Steven D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S82 - S82
  • [33] Amifostine in the treatment of low-risk myelodysplastic syndromes
    Grossi, A
    Fabbri, A
    Santini, V
    Leoni, F
    Nozzoli, C
    Longo, G
    Pagliai, G
    Ciolli, S
    Ferrini, PR
    HAEMATOLOGICA, 2000, 85 (04) : 367 - 371
  • [34] Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
    Melosky, B. L.
    CURRENT ONCOLOGY, 2008, 15 : S10 - S15
  • [35] Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes
    Caballero, Juan Carlos
    Davila, Julio
    Lopez-Pavia, Maria
    Such, Esperanza
    Bernal, Teresa
    Ramos, Fernando
    Calabuig, Marisa
    Sanchez, Jesus Maria Hernandez
    Pomares, Helena
    Barba, Mercedes Sanchez
    Abaigar, Maria
    Gonzalez, Bernardo
    Merchan, Brayan
    Sancho-Tello, Reyes
    Callejas, Marta
    Munoz-Novas, Carolina
    Cervero, Carlos
    Sanz, Guillermo
    Rivas, Jesus Maria Hernandez
    Campelo, Maria Diez
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [36] Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
    Itzykson, R.
    Thepot, S.
    Beyne-Rauzy, O.
    Ame, S.
    Isnard, F.
    Dreyfus, F.
    Salanoubat, C.
    Taksin, A. L.
    Chelgoum, Y.
    Berthon, C.
    Malfuson, J. V.
    Legros, L.
    Vey, N.
    Turlure, P.
    Gardin, C.
    Boehrer, S.
    Ades, L.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2012, 36 (04) : 397 - 400
  • [37] Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis
    Victor Moyo
    Patrick Lefebvre
    Mei Sheng Duh
    Behin Yektashenas
    Suneel Mundle
    Annals of Hematology, 2008, 87 : 527 - 536
  • [38] MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS: EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE
    Cerchione, C.
    Vitagliano, O.
    Simeone, L.
    Pareto, A. E.
    Soriente, I.
    D'arco, A. M.
    Danise, P.
    Alfinito, F.
    Pane, F.
    LEUKEMIA RESEARCH, 2015, 39 : S104 - S104
  • [39] MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS: EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE
    Cerchione, C.
    Vitagliano, O.
    Simeone, L.
    Pareto, A. E.
    Cerciello, G.
    Soriente, I.
    D'Arco, A. M.
    Danise, P.
    Alfinito, F.
    Pane, F.
    HAEMATOLOGICA, 2015, 100 : 166 - 167
  • [40] Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis
    Moyo, Victor
    Lefebvre, Patrick
    Duh, Mei Sheng
    Yektashenas, Behin
    Mundle, Suneel
    ANNALS OF HEMATOLOGY, 2008, 87 (07) : 527 - 536
12345